Please login to the form below

Not currently logged in
Email:
Password:

Lonza

This page shows the latest Lonza news and features for those working in and with pharma, biotech and healthcare.

KaloBios files for bankruptcy protection

KaloBios files for bankruptcy protection

Miami and a number of contractors including Lonza, Catalent, INC Research and PPD.

Latest news

  • BMS expand biologics manufacturing deal with Lonza BMS expand biologics manufacturing deal with Lonza

    BMS expand biologics manufacturing deal with Lonza. Will make wider use of New Hampshire facilities ahead of product launch. ... Bristol-Myers Squibb and Lonza have entered a multi-year expansion of their existing biologics manufacturing agreement.

  • AbbVie unveils its first Asian manufacturing plant AbbVie unveils its first Asian manufacturing plant

    Aside from AbbVie, companies such as GlaxoSmithKline, Lonza, Merck &Co, Novartis, Pfizer and Sanofi have all chosen to locate manufacturing facilities in Singapore, and the headcount in the country's biomedical

  • DSM merges pharma unit with Patheon DSM merges pharma unit with Patheon

    Patheon after beating out Lonza in a bidding war in 2009.

  • Baxter taps Coherus for Enbrel biosimilar Baxter taps Coherus for Enbrel biosimilar

    It also comes shortly after Teva and Lonza dissolved their biosimilar partnership, blaming the high level of investment required and the regulatory complexity of bringing them to market, although market research

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Lonza ends biosimilars deal with Teva. Chemical firm cuts losses after four-year development deal. ... Teva and Lonza have agreed to terminate a deal to develop a series of biologics, including biosimilars.

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics.

  • Deal Watch December 2016 Deal Watch December 2016

    Headline $m. Capsugel (US). Lonza (Switzerland). Acquisition. Oral delivery technologies, development, formulation and manufacturing for pharma, consumer and nutrition products. ... LifeCell. Allergan. 12.3%. Vascular Solutions. Teleflex. 8.8%. Capsugel.

  • Biosimilars in China Biosimilars in China

    Several joint venture deals between MNCs and Chinese players have been sealed recently: Hisun with Pfizer, Simcere with Merck and Fosun with Lonza.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics